创伤患者输血与医院感染呈剂量依赖性关联:PAMPer试验二次分析
该研究为PAMPer试验的二次分析,纳入住院时间≥3天的399例创伤患者,评估输血与医院感染的关系。结果显示27%发生医院感染,接受任何PRBC输血者感染风险增加两倍(OR 2.15,95%CI 1.01-4.58,p=0.047),且PRBC数量与感染风险独立相关(OR 1.10,95%CI 1.05-1.16,p<0.001)。提示创伤患者输血可能增加医院感染风险,且存在剂量效应,临床需权衡输血利弊。
要点
- 创伤患者接受至少1U PRBC输血与医院感染风险增加两倍独立相关(OR 2.15,95%CI 1.01-4.58,p=0.047)。
- PRBC输注数量与医院感染风险呈剂量依赖性关联(每单位OR 1.10,95%CI 1.05-1.16,p<0.001)。
- 研究纳入PAMPer试验中住院时间≥3天的399例创伤患者,27%发生医院感染,最常见为肺炎(67例)。
- 输血相关感染风险增加在调整年龄、性别和损伤严重度评分后仍显著。
- 该研究为二次分析,证据等级为治疗/临床管理level IV,不能证明因果关系。
适用人群与场景
- PAMPer试验中住院时间至少3天的创伤患者,共399例;年龄中位数46岁(IQR 29-59),损伤严重度评分中位数22(IQR 12-29),73%男性,80%钝性损伤。
- 排除标准未在原文明确提及,但仅纳入住院时间≥3天的患者。
诊断标准与关键阈值
- 医院感染诊断包括肺炎、血流感染、导管相关尿路感染、皮肤软组织感染、艰难梭菌结肠炎、脓胸和复杂性腹腔感染,具体诊断标准原文未提及。
- 输血暴露定义为接受任何PRBC输血或PRBC输注数量。
处置流程与药物剂量
- 原文未提及具体输血策略或剂量推荐;仅分析输血与感染关联,未给出干预方案。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:PAMPer试验的二次分析,纳入399例住院时间≥3天的创伤患者,来自PAMPer试验的多中心数据(中心数原文未提及)。
- 接受任何PRBC输血与医院感染风险增加相关(OR 2.15,95%CI 1.01-4.58,p=0.047),调整年龄、性别和损伤严重度评分。
- PRBC输注数量与医院感染风险独立相关(OR 1.10,95%CI 1.05-1.16,p<0.001),呈剂量依赖性。
- 其他血制品:12%接受冷沉淀,69%接受血浆,27%接受血小板;原文未报告其与感染的关联。
- 死亡率10%(40例)。
证据类型、等级与局限
- 证据类型:前瞻性收集数据的二次分析(PAMPer试验),证据等级为治疗/临床管理level IV。
- 局限:二次分析、观察性关联不能证明因果关系;仅纳入住院时间≥3天患者可能存在选择偏倚;原文未提及单中心或多中心、盲法等细节。
对床旁实践的改变
- 该研究提示创伤患者接受PRBC输血与医院感染风险增加相关且呈剂量依赖性,临床输血决策时应更严格评估输血指征,避免不必要的PRBC输注。
- 适用人群:PAMPer试验中住院时间≥3天的创伤患者;不适用于非创伤患者或住院时间<3天者。
- 常见陷阱:不能将关联误认为因果;不能据此制定具体输血阈值;需结合患者个体情况权衡输血利弊。
指南或共识出处
- PAMPer试验(Prehospital Air Medical Plasma trial)的二次分析,发表于J Trauma Acute Care Surg;具体指南或共识名称原文未提及。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Prehospital Air Medical Plasma (PAMPer) trial demonstrated a survival benefit to trauma patients who received thawed plasma as part of early resuscitation. The objective of our study was to examine the association between blood transfusion and nosocomial infections among trauma patients who participated in the PAMPer trial. We hypothesized that transfusion of blood products will be associated with the development of nosocomial infections in a dose-dependent fashion.
METHODS: We performed a secondary analysis of prospectively collected data of patients in the PAMPer trial with hospital length of stay of at least 3 days. Demographics, injury characteristics, and number of blood products transfused were obtained to evaluate outcomes. Bivariate analysis was performed to identify differences between patients with and without nosocomial infections. Two logistic regression models were created to evaluate the association between nosocomial infections and (1) any transfusion of blood products, and (2) quantity of blood products. Both models were adjusted for age, sex, and Injury Severity Score.
RESULTS: A total of 399 patients were included: age, 46 years (interquartile range, 29-59 years); Injury Severity Score, 22 (interquartile range, 12-29); 73% male; 80% blunt mechanism; and 40 (10%) deaths. Ninety-three (27%) developed nosocomial infections, including pneumonia (n = 67), bloodstream infections (n = 14), catheter-associated urinary tract infection (n = 10), skin and soft tissue infection (n = 8), Clostridium difficile colitis (n = 7), empyema (n = 6), and complicated intra-abdominal infections (n = 3). Nearly 80% (n = 307) of patients received packed red blood cells (PRBCs); 12% received cryoprecipitate, 69% received plasma, and 27% received platelets. Patients who received any PRBCs had more than a twofold increase in nosocomial infections (odds ratio, 2.15; 95% confidence interval, 1.01-4.58; p = 0.047). The number of PRBCs given was also associated with the development of nosocomial infection (odds ratio, 1.10; 95% confidence interval, 1.05-1.16; p < 0.001).
CONCLUSION: Trauma patients in the PAMPer trial who received a transfusion of at least 1 U of PRBCs incurred a twofold increased risk of nosocomial infection, and the risk of infection was dose dependent.
LEVEL OF EVIDENCE: Therapeutic/care management, level IV.
参考来源
- Ladhani HA, Ho VP, Charbonnet CC, et al. Dose-dependent association between blood transfusion and nosocomial infections in trauma patients: A secondary analysis of patients from the PAMPer trial. J Trauma Acute Care Surg. 2021. PMID: 34397951. doi:10.1097/TA.0000000000003251
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。